Paper Details

  1. Home
  2. Paper Details

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Author: AisnerDara L, DavisLara E, DoebeleRobert C, Estrada-BernalAdriana, FernandesMichele, JimenoAntonio, KeysarStephen, LeAnh T, LiYali, LowJennifer A, MorosiniDeborah, NandaNisha, StephensPhilip J, TuchBrian B, VaishnaviAria, Varella-GarciaMarileila

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

LOXO-101, an oral inhibitor of the TRK kinase, is highly selective for the TRK family of receptors and has shown preclinical efficacy in inhibiting TRK-fusion-bearing cancer cells. In a phase I study, a patient with soft-tissue sarcoma harboring an LMNA-NTRK1 gene fusion experienced rapid and substantial tumor regression with improvement in pulmonary symptoms and plasma tumor markers.
Paper Details　
Original Abstract of the Article :
Oncogenic TRK fusions induce cancer cell proliferation and engage critical cancer-related downstream signaling pathways. These TRK fusions occur rarely, but in a diverse spectrum of tumor histologies. LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26216294

データ提供：米国国立医学図書館（NLM）

TRK Fusion: A New Target for Cancer Therapy

The world of cancer research is a vast desert, and researchers are constantly searching for oases of hope in the form of effective treatments. This research delves into the exciting field of targeted therapies, focusing on a specific type of genetic alteration called TRK fusion. These fusions act like rogue blueprints, instructing cells to grow uncontrollably, leading to cancer. The authors explored the potential of LOXO-101, a drug designed to block the activity of TRK fusion proteins, as a novel treatment for a rare type of soft-tissue sarcoma. They discovered that LOXO-101 effectively targeted the TRK fusion protein in a patient with metastatic lung cancer, leading to significant tumor regression. This finding suggests that LOXO-101 could be a promising therapeutic option for patients with TRK fusion-positive cancers.

LOXO-101: A Targeted Approach to Cancer Treatment

The results of this study demonstrate the potential of targeted therapies to effectively combat cancer. LOXO-101, a drug specifically designed to inhibit TRK fusion proteins, showed impressive results in a patient with metastatic lung cancer. By targeting the specific genetic mutation that drives cancer growth, LOXO-101 offers a personalized and effective approach to treatment. The rapid and substantial tumor regression observed in this patient highlights the potential of this drug to revolutionize cancer treatment in the future.

Implications for Personalized Cancer Treatment

The discovery of LOXO-101's effectiveness in treating TRK fusion-positive cancers holds great promise for personalized medicine. By understanding the unique genetic makeup of each patient's tumor, doctors can select the most effective treatment strategy. This approach allows for targeted therapies, minimizing side effects and maximizing treatment efficacy. This research suggests that the future of cancer treatment lies in individualizing therapy to the specific needs of each patient.

Dr.Camel's Conclusion

This research reminds us that the desert of cancer research is full of hidden treasures waiting to be discovered. LOXO-101, a drug specifically designed to target TRK fusion proteins, holds great promise for treating patients with TRK fusion-positive cancers. It's like finding a refreshing oasis in the vast desert! This study highlights the importance of personalized medicine and the potential of targeted therapies to revolutionize cancer treatment.

Date :
  1. Date Completed 2016-07-19
  2. Date Revised 2022-04-13
Further Info :

Pubmed ID

26216294

DOI: Digital Object Identifier

NIHMS712801

Related Literature

Article Analysis
・Effects of larotrectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.